OncoHost Receives New York State Laboratory Permit for Precision Oncology Test
The permit enables the company to offer its PROphetNSCLC test to physicians and patients across New York State, completing nationwide availability.
Category: Lung Cancer
Lung Cancer
Latest
Lung Cancer
Latest
Breakthrough Device Designation Granted for Roche’s VENTANA TROP2 RxDx Device
Roche's VENTANA TROP2 RxDx Device, a computational companion diagnostic, has received FDA Breakthrough Device Designation.
Lung Cancer
Latest
Biofidelity’s Aspyre Lung Delivers Accurate Molecular Diagnostics for NSCLC Variants
Studies validated Biofidelity’s Aspyre Lung diagnostic tech, showcasing its ability to offer genomic profiling for actionable NSCLC variants.
Detecting Evidence of Lung Cancer in Exhaled Breath
Researchers developed a sensor that can detect low levels of isoprene in exhaled breath, potentially enabling early lung cancer diagnosis.
Read More
NeoGenomics’ Solid Tumor Test Gets New York State Approval
NeoGenomics received conditional approval from the New York State Department of Health for its Neo Comprehensive Solid Tumor and NeoTYPE DNA & RNA Lung assays.
Read More
BioAffinity Awarded US Federal Supply Schedule Contract for Noninvasive Lung Test
BioAffinity Technologies’ noninvasive lung cancer test is available to Veterans and military personnel for early-stage lung cancer detection.
Read More
Breakthrough Lung Cancer Blood Test is 14 Times More Sensitive
A new microchip uses exosome analysis to detect lung cancer from a simple blood draw, enhancing speed and sensitivity in cancer diagnostics.
Read More
PathAI Adds MET Predict to AISight for NSCLC Assessments
The MET Predict assists in identifying NSCLC tumors with MET exon 14 skipping or MET amplification directly from H&E whole slide images.
Read More
DELFI Diagnostics Taps New CFO
Summary: DELFI Diagnostics appointed Thomas Russo as its new CFO to support the company’s...
Read More
AI-Powered Digital Pathology Platform Aids Lung Cancer Diagnosis
A new AI-driven digital pathology platform enables fully automated, rapid, and accurate analysis of lung cancer tissue.
Read More
Open Comment Period to Revise Molecular Testing Guidelines in Lung Cancer Treatment Announced
Several diagnostic associations announced the open comment period for the revised 2018 guideline on molecular testing for lung cancer.
Read More
New Test Influences First-Line Therapy Decisions for Metastatic NSCLC Patients
A new study from OncoHost reveals that its PROphetNSCLC test impacts oncologists’ first-line treatment decisions for metastatic NSCLC.
Read More
Development of Breath Test for Lung Disease is Underway
Researchers have developed a potential exhaled-breath test for lung diseases by successfully collecting lung biomarkers from human breath.
Read More
AI Blood Test Reliably Identifies Lung Cancer
Researchers have developed an AI-powered liquid biopsy to identify lung cancer earlier through DNA fragment patterns in blood.
Read More
DELFI Diagnostics’ Blood Test Validated for Early Lung Cancer Detection
DELFI’s blood-based Lung test has been clinically validated to enhance early detection of lung cancer, demonstrating high sensitivity.
Read More
PROphet Platform’s Predictive Ability to be Demonstrated
OncoHost will highlight the PROphet platform’s capability to predict benefits from therapies across various cancers.
Read More
DELFI Collaborates with Hospital System to Improve Lung Cancer Screening
OSF HealthCare will use DELFI’s FirstLook Lung blood test to enhance lung cancer screening rates and early detection efforts.
Read More
CAP Publishes Guideline for PD-L1 Testing of Lung Cancer Patients
CAP developed recommendations for testing immunotherapy biomarkers, such as PD-L1 and TM), in patients with NSCLC.
Read More